Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Measuring calcium intake can help to identify osteoporosis in men with prostate cancer

10.04.2007
Measuring a man’s daily calcium intake is an effective way of identifying prostate cancer patients with a higher than average risk of osteoporosis, according to the April issue of the urology journal BJU International.

Researchers from the Autonoma University School of Medicine, Barcelona, Spain, looked at a cross-section of 372 men with prostate cancer. 72 per cent were receiving androgen-deprivation therapy (ADT) and 28 per cent had undergone a radical prostatectomy. Their average age was just under 70.

They found that 49 per cent of the men had osteoporosis, including 55 per cent of those who had received the ADT hormone therapy and 35 per cent of those who had had a prostatectomy.

These figures are considerably higher than the prevalence of osteoporosis in the general male population, where it’s estimated that about 20 per cent of all male osteoporosis cases occur in the 61 to 70 age group.

A dietary questionnaire revealed that only seven per cent of the men were consuming more than 1000 mg of calcium a day - the average daily calcium intake was 610mg in men with osteoporosis and 683mg in those without.

These levels are well below the 1000mg recommended for all 25-65 year-olds by the US National Institutes of Health and the 1500mg recommended for men over 65.

“Our research showed a significant relationship between a low daily calcium intake and higher levels of osteoporosis in men with prostate cancer” says lead researcher Dr Jacques Planas from the University’s Department of Urology.

“Men who had undergone ADT hormone therapy were particularly at risk and longer treatment and increased age were also related to higher levels of osteoporosis.

“What was particularly interesting was the fact that more than a third of the patients who hadn’t received hormone treatment also developed osteoporosis.”

Osteoporosis is caused by loss of bone mineral density, which makes bones brittle and significantly more likely to fracture. It is more common in older people and has been strongly linked to hormonal changes, such as the female menopause.

Links to ADT hormone therapy have also been reported, but the Barcelona study is thought to be the first to look at using daily calcium as a diagnostic tool to identify prostate cancer patients who face an increased risk of osteoporosis, including those who have not received ADT.

“Men account for about a third of all hip fractures, but they are much more likely to die after an injury of this nature than women, so it is important to identify possible risks at an early stage” adds Dr Planas.

Hormone treatment ranged from 12 to 98 months, with an average of just over 42 months. Men with bone disorders or secondary causes of osteoporosis were excluded from the study.

As well as the dietary questionnaire, the men taking part in the study had their bone mineral density measured at the lumbar spine and four different hip sites in line with the guidelines developed by the International Society for Clinical Densitometry for the diagnosis of osteoporosis.

“We carried out our research to discover whether there was a relationship between low daily calcium intake and reduced bone mineral density, which there clearly was” say Dr Planas.

“We also wanted to know if daily calcium intake could be used as a prognostic factor for osteoporosis, especially for patients receiving ADT. Our research suggests that it does provide a good pointer to whether a prostate cancer patient also has osteoporosis.”

The authors suggest that patients with prostate cancer should be routinely advised to take at least 1000mg of calcium a day and that their bone mineral density should be assessed, particularly before starting ADT, and monitored at regular intervals after the treatment begins.

Annette Whibley | alfa
Further information:
http://bjui.org
http://www.blackwellpublishing.com

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>